Independent journalism from St. Vincent and the GrenadinesSupport VPNNewsletterAdvertiseYouTubeContact
VINCYPOWA NEWSPower to the People

Independent journalism from St. Vincent and the Grenadines, for the Caribbean and the world.

, , ,

Anthropic Stock Jumps 17% in Nasdaq Debut as CEO’s Disease-Cure Claim Draws Fire

Anthropic Stock Jumps 17% in Nasdaq Debut as CEO’s Disease-Cure Claim Draws Fire

Investors bid up the Claude maker’s shares on day one, while doctors, including Germany’s former health minister, kept pushing back on Dario Amodei’s pitch that AI could end major diseases in under ten years.

Vincypowa News graphic: Anthropic stock jumps 17% in its Nasdaq debut, closing at $97.17 against an $83 IPO price, as doctors push back on CEO Dario Amodei's claim that AI could end major diseases within a decade

Anthropic stock closed its first day of trading up about 17 percent on Thursday, November 19, as the maker of the Claude AI models made its debut on Nasdaq under the ticker ANT. The rally came as doctors continued to challenge the company’s boldest selling point: CEO Dario Amodei’s claim that AI could make cancer, Alzheimer’s disease, heart disease, and mental illness “relics of the past” in less than a decade.

How Anthropic stock performed on day one

Anthropic priced its initial public offering at $83 a share on Wednesday, above its marketed range of $70 to $78, as Vincypowa News reported. The stock opened on the Nasdaq Global Select Market at $111.50 and closed the day at $97.17, giving the company a market value of roughly $1.27 trillion.

The Anthropic CEO’s pitch: AI cures within a decade

The medical prediction came in a 42-minute IPO roadshow video released on November 10, which Vincypowa News first covered that week. Amodei framed it around the idea that powerful AI could compress 50 to 100 years of biomedical progress into five to ten years, a view he first set out in his October 2024 essay “Machines of Loving Grace.”

Anthropic points to early results from its life sciences partnerships with six organizations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. In an October update, the company said Claude generated roughly 35,000 antibody designs in about a month for a potential food allergy treatment at Divergence Labs, with early lab tests identifying promising candidates. At Generate Biomedicines, scientists used Claude Code to redesign part of a CAR T-cell cancer therapy. One design was about 70 percent shorter than the standard version and, in lab tests, helped immune cells produce about ten times as many cancer-targeting receptors.

Anthropic has said the work is early and largely preclinical, meaning none of these treatments has reached human trials.

Doctors push back on the Anthropic stock pitch

Medical experts say the timeline does not match how medicine works. Complex diseases involve biological, clinical trial, and regulatory hurdles that AI has not yet shown it can clear at that speed.

Karl Lauterbach, a physician and Germany’s former health minister, wrote on X that AI can certainly help research into cancer, Alzheimer’s, and mental illness, but that curing them in just ten years is impossible. He also questioned whether Amodei knows too little about medicine or is deliberately misleading the public.

What comes next for Anthropic stock

The cure claim was one part of a wider pitch to public market investors about AI’s benefits to society, and day one suggests many buyers were willing to bet on it. Whether Anthropic’s biomedical partnerships produce approved treatments on any faster timeline will be decided through the standard clinical trial process, a test measured in years rather than trading sessions.

Vincypowa News is independent and self-funded. We apply the same scrutiny to every government. Spotted an error? Tell us and we will correct it. Our standards

Get the VPN Morning Brief

The day’s most important SVG and Caribbean stories, free in your inbox before work.

Support independent journalism

Vincypowa News is self-funded, with no party, government or corporate backers. If this reporting matters to you, help keep it free for everyone.

Support VPN from $5
Your turn

Join the conversation

What do you think? Share your view below. Disagreement is welcome; personal attacks are not. Comments are moderated.

Leave a Reply